NAV

Corticorelin

Identification

Summary

Corticorelin is a synthetic corticotropin-releasing factor analog used to diagnose causes of excessive adrenocorticotropic hormone (ACTH) production.

Generic Name
Corticorelin
DrugBank Accession Number
DB05394
Background

Corticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.

Type
Small Molecule
Groups
Investigational
Synonyms
  • Corticoliberin human
  • Corticorelin
  • Corticorelin (human)
  • Corticotropin releasing hormone human
  • Corticotropin-releasing factor
  • Corticotropin-releasing factor (human)
  • Corticotropin-releasing hormone
  • CRF
  • hCRF
  • Human corticoliberin
  • Human corticotropin-releasing factor
External IDs
  • NEU-3002

Pharmacology

Indication

Investigated for use/treatment in brain cancer and neurologic disorders.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Corticotropin-releasing factor is produced by neuroendocrine cells in the paraventricular nucleus of the hypothalamus and is released from neurosecretory terminals of these neurons into the primary capillary plexus of the hypothalamo-hypophyseal portal system. The portal system carries the Corticotropin-releasing hormone(CRH) to the anterior lobe of the pituitary where it stimulates the secretion of corticotropin (ACTH) and other biologically active substances.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
V04CD04 — Corticorelin
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
305OE8862Y
CAS number
86784-80-7

References

General References
  1. Hoare SR, Sullivan SK, Ling N, Crowe PD, Grigoriadis DE: Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol Pharmacol. 2003 Mar;63(3):751-65. [Article]
  2. Lowery EG, Sparrow AM, Breese GR, Knapp DJ, Thiele TE: The CRF-1 receptor antagonist, CP-154,526, attenuates stress-induced increases in ethanol consumption by BALB/cJ mice. Alcohol Clin Exp Res. 2008 Feb;32(2):240-8. Epub 2007 Dec 21. [Article]
  3. Panickar KS: Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema. Curr Opin Mol Ther. 2010 Dec;12(6):780-9. [Article]
PubChem Substance
347910116
RxNav
214461
Wikipedia
Corticotropin-releasing_hormone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceHealthy Subjects (HS)1
3CompletedTreatmentBrain Neoplasm / Brain Swelling2
3WithdrawnTreatmentBrain Neoplasm / Brain Swelling1
1Active Not RecruitingBasic ScienceSleep Restriction1
1CompletedBasic ScienceStress (Psychology)1
1CompletedTreatmentEdema1
1, 2TerminatedTreatmentBrain Neoplasm / Brain Swelling1
0Active Not RecruitingBasic ScienceSleep Restriction1
Not AvailableCompletedNot AvailableAdrenal Gland Hyperfunction / Adrenal Gland Hypofunction / Cushing's Syndrome / Healthy Subjects (HS)1
Not AvailableCompletedNot AvailableCocaine Related Disorders / Dependence, Cocaine / Substance Related Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionParenteral100 μg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Enzymes

Details1. Dopamine beta-hydroxylase
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
L-ascorbic acid binding
Specific Function
Conversion of dopamine to noradrenaline.
Gene Name
DBH
Uniprot ID
P09172
Uniprot Name
Dopamine beta-hydroxylase
Molecular Weight
69064.45 Da
References
  1. Lima L, Sourkes TL: Effect of corticotropin-releasing factor on adrenal DBH and PNMT activity. Peptides. 1987 May-Jun;8(3):437-41. [Article]

Drug created at November 18, 2007 18:24 / Updated at March 20, 2023 08:24